PP1815
AXP000230.1 · Phage therapy
- Platform
- single phage, solution for injection
- Originator
- Pherecydes Pharma
- Sponsor
- Phaxiam Therapeutics
Names
| Name | Type | Source |
|---|---|---|
| PP1815 | preferred name, code | curator, curator |
Virus
- Role
- Phage
- Family
- Caudoviricetes
- Virus
- Staphylococcus aureus bacteriophage
- Replication
- replicating
- Route
- intravenous, inhaled
- Source
- evidence
Approvals
No regulatory approval recorded.
Clinical trials (1)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT06605651 | Proof of Concept Study to Assess Safety and Efficacy of Phage Therapy in Hip or Knee Prosthetic Joint Infections Due to Staphylococcus Aureus Treated by DAIR. | Not yet recruiting | Phase 2 | 2026-07 | 2028-03 | 100 | Hip Prosthesis Infection; Knee Prosthesis Infection |
Recent changes
No changes recorded in its trials yet.
Notes
Anti-Staphylococcus aureus phage, solution for injection, used alongside PP1493 under French compassionate access and in PhagoDAIR I NCT05369104 and PhagoDAIR II NCT06605651. See PP1493 for why the two are separate programs.
How to cite
PP1815 (AXP000230.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000230.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.